Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. Uses of biomarkers in breast cancer (1)
3. Uses of biomarkers in breast cancer (2)
4. Why we need prognostic biomarkers
5. Prognostic biomarkers in breast cancer
6. Prognostic biomarkers proposed for breast cancer
7. So many described but so few in clinical use
8. Requirements for a useful prognostic biomarker
9. Examples of prognostic biomarkers
10. Estrogen receptor (ER) as a prognostic biomarker
11. HER2 as a prognostic biomarker
12. uPA and PAI-1 as prognostic biomarkers (1)
13. uPA and PAI-1 as prognostic biomarkers (2)
14. uPA/PAI-1: prognostic value in breast cancer
15. Pooled analysis of uPA/PAI-1: EORTC study
16. Pooled analysis: summary
17. uPA and PAI-1 as prognostic biomarkers trial (1)
18. uPA and PAI-1 as prognostic biomarkers trial (2)
19. uPA and PAI-1: ASCO recommendation (1)
20. uPA and PAI-1: ASCO recommendation (2)
21. uPA and PAI-1: EGTM recommendation
22. uPA and PAI-1: NACB recommendation (1)
23. uPA and PAI-1: NACB recommendation (2)
24. Ki67 as a prognostic biomarker in breast cancer
25. Multiparamater prognostic tests (1)
26. Multiparamater prognostic tests (2)
27. Oncotype DX (1)
28. Oncotype DX (2)
29. Oncotype DX test: ASCO recommendations
30. Predictive biomarkers in breast cancer (1)
31. Why we need predictive biomarkers (1)
32. Why we need predictive biomarkers (2)
33. Predictive biomarkers in breast cancer (2)
34. ER for identifying early or advanced disease
35. Using ER for predicting hormone therapy response
36. Benefit of tamoxifen in ER-positive early disease
37. Benefit of tamoxifen in ER-positive patients
38. The use of HER2
39. Rationale for using HER2 status (1)
40. Rationale for using HER2 status (2)
41. Trastuzumab in HER2-positive early breast cancer
42. Trastuzumab in HER2-positive advanced disease
43. Trastuzumab in treatment of breast cancer
44. Different types of systemic therapy
45. How does a doctor decide which therapy to use?
46. Use of ER and HER2 in directing therapy
47. Use of biomarkers in postoperative surveillance
48. List of biomarkers in postoperative surveillance
49. Postoperative surveillance: pros
50. Postoperative surveillance: cons
51. Postoperative surveillance following diagnosis
52. Do these findings still hold?
53. CA 15-3 in surveillance following surgery
54. Biomarkers therapy monitoring: advanced disease
55. Aims of treatment in advanced disease
56. ASCO guidelines for CA 15-3 monitoring
57. EGTM guidelines for CA 15-3 monitoring
58. Caveats during surveillance and therapy monitoring
59. Where new biomarkers are most urgently needed
60. Thank you

Topics Covered

• Biomarkers role in determining prognosis in breast cancer
• Therapy prediction
• Postoperative surveillance -Monitoring therapy
• Estrogen receptor
• HER2
• uPA/PAI-1
• Oncotype DX
• CA 15-3

Links

Series:

• Biomarkers

Categories:

• Cancer
• Clinical Practice
• Pharmaceutical Sciences

Therapeutic Areas:

• Oncology

Talk Citation

Publication History

• Published on September 27, 2012

Financial Disclosures

• Prof. Joe Duffy has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.